GSA Capital Partners LLP Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

GSA Capital Partners LLP increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,762 shares of the medical equipment provider’s stock after buying an additional 1,048 shares during the period. GSA Capital Partners LLP’s holdings in Hologic were worth $469,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC purchased a new position in shares of Hologic in the third quarter worth about $25,000. Innealta Capital LLC purchased a new position in shares of Hologic in the second quarter worth about $25,000. iA Global Asset Management Inc. bought a new position in shares of Hologic in the first quarter valued at approximately $37,000. Sunbelt Securities Inc. bought a new position in shares of Hologic in the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC boosted its position in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 0.7 %

Shares of HOLX opened at $78.04 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The firm has a 50 day moving average price of $80.52 and a 200-day moving average price of $78.30. The firm has a market cap of $18.13 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the previous year, the firm earned $0.89 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, equities research analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and cut their price objective for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.